A recent analysis of the new anticoagulants to replace Coumadin (Warfarin) is looking quite favorable when treating blood clots. This is expanding their indication, usage and safety.
In the U.S. the two alternatives are PRADAXA and XARELTO, with Xarelto appearing to be somewhat more advantageous with less issues from bleeding.
Such alternatives are sorely needed and provide a great deal of benefit as regards convenience as they do not require blood monitoring.
On the other hand, there is no ready ‘antidote’ to these new anticoagulants, and until more experience accumulates as to their safety in various populations, we will remains slow to adopt their usage across the board.
Read more if you are interested:
http://www.bmj.com/content/345/bmj.e7498